Cipla seeks voluntary licence for J&J's HIV drug rilpivirine
This article was originally published in Scrip
Executive Summary
Cipla has sought a voluntary licence to make a cut-price version of Johnson & Johnson subsidiary Tibotec Pharmaceuticals' HIV drug rilpivirine (Edurant), its second such request in the recent past after the Indian firm sought similar permission for Merck & Co's Isentress (raltegravir).